Licensing, Acquisitions and Other Arrangements (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	6 Months Ended
	May. 26, 2015	Mar. 31, 2015	Jun. 30, 2015	May. 31, 2015
Term loan facility | Bridge Term Loan Agreement
Collaborations and Other Arrangements
Debt term		364 days
Drawn amount		$ 0
Maximum borrowing of term loan facility		$ 18,000
Senior notes
Collaborations and Other Arrangements
Debt face amount				$ 16,700
Pharmacyclics Inc
Collaborations and Other Arrangements
Percentage of cash consideration	58.00%
Percentage of share consideration	42.00%
Shares issued as consideration	128,000,000
Aggregate purchase price			$ 20,770
Cash consideration paid	$ 12,400
Fair value of AbbVie common stock issued to Pharmacyclics stockholders			8,405
Cash consideration paid to Pharmacyclics stockholders			11,749
Cash consideration paid to Pharmacyclics equity award holders			616
Total consideration			$ 20,770
Maximum period of valuation	1 year
Pharmacyclics Inc | Scenario One
Collaborations and Other Arrangements
Purchase price payment partly in cash (in dollars per share)	$ 152.25
Purchase price payment partly in fair market value of shares of acquirer's common stock (in dollars per share)	109.00
Pharmacyclics Inc | Scenario Two
Collaborations and Other Arrangements
Purchase price payment fully in cash (in dollars per share)	261.25
Pharmacyclics Inc | Scenario Three
Collaborations and Other Arrangements
Purchase price payment fully in fair market value of shares of acquirer's common stock (in dollars per share)	$ 261.25